NDA 020895 · Viatris
Viagra
Sildenafil Citrate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Dec 14, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Mar 27, 1998
Approved uses
3
Original approval plus efficacy supplements
Registered trials
439
87 Phase 3, 20 recruiting
FAERS reports
60,910
33,452 serious, 4,495 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 29, 2024.
Sildenafil citrate tablets are indicated for the treatment of erectile dysfunction. Sildenafil citrate tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) ( 1 )
Mechanism: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 11, 2014 Supplement 42 · Efficacy LetterLabel
- Sep 19, 2002 Supplement 18 · Efficacy LabelLetter
- Mar 27, 1998 Original approval · Type 1 - New Molecular Entity · priority review LetterLabelReview
3 products under this application
- VIAGRA · SILDENAFIL CITRATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
- VIAGRA · SILDENAFIL CITRATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
- VIAGRA · SILDENAFIL CITRATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sildenafil" as an intervention, any sponsor and status, largest first.
- Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across NationsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00547287 · 2,760 participants · Start Nov 2002
Drug: tadalafil; sildenafil · For: Impotence
Sites: São Paulo, Brazil
- Cost-effective Treatment of Unexplained InfertilityPivotal-lookingCompleted
Batterjee Medical CollegeAcademic, hospital or other
NCT06178523 · 900 participants · Start Jan 1, 2024 · Primary completion Dec 31, 2024
Drug: Clomiphene Citrate.; Sildenafil Citrate · For: Unexplained Infertility
Sites: Jeddah, Saudi Arabia
- A Study to Evaluate Self-esteem and Relationships in Males With Erectile DysfuntionPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00648596 · 780 participants · Start May 2003
Drug: sildenafil; placebo · For: Erectile Dysfunction
Sites: Oulu, Finland; Tampere, Finland; Turku, Finland · 66 sites in all
- A Study in Patients With Erectile DysfunctionPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01122264 · 770 participants · Start May 2010 · Primary completion Jun 2011
Drug: Tadalafil; Sildenafil Citrate · For: Erectile Dysfunction
Sites: Carpentras, France; Chambéry, France; La Bouëxière, France · 45 sites in all
- Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo TransferPivotal-lookingCompleted
Wael Elbanna ClinicAcademic, hospital or other
NCT03945812 · 665 participants · Start Jun 1, 2019 · Primary completion Mar 31, 2022
Drug: Granulocyte Colony Stimulating Factor · For: Infertility; Frozen Embryo Transfer (FET)
Sites: Maadi, Egypt
- Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00457457 · 609 participants · Start May 2007 · Primary completion Apr 2008
Drug: Tamsulosin; UK-369,003 · For: Prostatic Hyperplasia
Sites: Herston, Australia; Adelaide, Australia; Brussels, Belgium · 46 sites in all
- Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.Pivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00249730 · 510 participants · Start Oct 2005
Drug: Sildenafil · For: Impotence
Sites: Kitchener, Canada; Sarnia, Canada; Toronto, Canada · 39 sites in all
- Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder PatientsPivotal-lookingRecruiting
Mansoura UniversityAcademic, hospital or other
NCT07391579 · 500 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2026
Drug: Tadalafil 5 mg & Sildenafil 100mg; Sildenafil 100mg & placebo · For: Erectile Dysfunctions
Sites: Al Mansurah, Egypt; Alexandria, Egypt; Aswān, Egypt · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective10,621
- headache5,105
- dyspnoea4,383
- erection increased2,999
- diarrhoea2,910
- fatigue2,797
- nausea2,676
- dizziness2,602
- cough2,306
- death2,187
- pain1,820
- malaise1,689
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 987 |
| 2005 | 1,340 |
| 2006 | 1,598 |
| 2007 | 955 |
| 2008 | 924 |
| 2009 | 894 |
| 2010 | 4,072 |
| 2011 | 2,002 |
| 2012 | 2,790 |
| 2013 | 2,909 |
| 2014 | 3,394 |
| 2015 | 4,061 |
| 2016 | 4,002 |
| 2017 | 4,367 |
| 2018 | 3,396 |
| 2019 | 4,504 |
| 2020 | 3,692 |
| 2021 | 2,619 |
| 2022 | 2,638 |
| 2023 | 2,543 |
| 2024 | 2,613 |
| 2025 | 2,606 |
| 2026 | 2,004 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Viagra (Sildenafil Citrate)
2024 spending
$165K
Beneficiaries
92
398 claims
Per beneficiary
$1,792
$82.10 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,054,229 |
| 2021 | $729,142 |
| 2022 | $531,483 |
| 2023 | $333,640 |
| 2024 | $164,848 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sildenafil improves clinical signs and radiographic features in dogs with congenital idiopathic megaoesophagus: a randomised controlled trial.
Quintavalla F, Menozzi A, Pozzoli C, et al. · Vet Rec 2017 · Randomized Controlled Trial
- Sildenafil for pulmonary hypertension.
Kanthapillai P, Lasserson T, Walters E · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Sildenafil affects olfactory function.
Gudziol V, Mück-Weymann M, Seizinger O, et al. · J Urol 2007 · Randomized Controlled Trial
- Is Continuous Positive Airway Pressure a Valid Alternative to Sildenafil in Treating Sexual Dysfunction among OSA Patients? A Systematic Review and Meta-Analysis.
Stilo G, Vicini C, Pollicina I, et al. · Medicina (Kaunas) 2023 · Meta-Analysis, Systematic Review
- Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.
Fang J, Zhang P, Zhou Y, et al. · Nat Aging 2021 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis.
Abouelmagd ME, Abdelmeseh M, Elrosasy A, et al. · Neurol Sci 2024 · Systematic Review, Meta-Analysis
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.